Paul D’Souza
Editor
Clarivate Analytics
London
United Kingdom

Powered by

The mergers and acquisitions (M&A) activity in the life sciences sector in the third quarter of 2016 continued showing an important activity for both number of deals and financial value.
In the previous three months, 124 active M&A deals were reported by Clarivate Recap, a 4.2% increase from 119 deals in the second quarter, however, the total disclosed value decreased by 67% from $116.3 billion to $38.3 billion (Figure 1).

Deal activity in 3rd Quarter
In the third quarter of the year, Pfizer targeted Medivation, developer of blockbuster anti-prostate treatment Xtandi, which it shares with Astellas to bolster its immune-oncology portfolio. Johnson & Johnson improved its Vision Care operations with Abbott’s cataract eye surgery business. Other large M&As also follow.

Pfizer to acquire anti-prostate Xtandi developer Medivation for $14 billion
The lucrative breast ... ...